Alcidion Reviews

Thank you for your review. We acknowledge a period of change can be difficult for everyone impacted. Recognising the need to balance our current revenue with the cost base and having completed several major customer project deliverables in 2023, we recently concluded a program to reduce our annual cost base, principally through a reduction in headcount. We acknowledge the important contribution those departing have made to Alcidion and wish them every success in the future. Whilst short term revenue growth has been impacted by a challenging healthcare procurement environment, Alcidion remains well positioned in the long-term with $126M of sold and renewal revenue already committed over the next five years and a growing pipeline of tender opportunities.